Cluster Health & Mission Cancer Brokerage Event

28 Sept 2026 | Brussels, Belgium

Project cooperationUpdated on 7 September 2026

Policies for cancer patients

Executive Director at Association of European Cancer Leagues (ECL)

Brussels, Belgium

About

ECL actively contributes to numerous EU-funded research and public health initiatives. In partnership with over 70 partners – including cancer leagues, research institutes, public health organisations, university hospitals, and academic experts – we work to drive progress in cancer prevention and care across Europe.

By using our strong network of partners and fostering connections between researchers, policymakers, and key stakeholders, we help ensure that the findings from EU-funded projects are translated into real-world impact. Our core contributions to these projects include stakeholder engagement, policy recommendations, strategic communications, and dissemination of results.

ECL is also proud to participate in several EU Joint Actions – collaborative initiatives that unite national health authorities, public institutions, and other key stakeholders from multiple EU member states to address specific challenges in cancer prevention, diagnosis, treatment, or care.
As coordinators and consortium partners in various impactful EU projects and Joint Actions, we are committed to strengthening Europe’s collective fight against cancer.

Topic

  • Healthcare innovations: HORIZON-MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
  • Healthcare innovations: HORIZON-MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
  • Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
  • Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
  • Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes

Similar opportunities